secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000914475-23-000075
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine settles Lupin patent litigation; generic INGREZZA entry set for March 1, 2038
--------------------------------------------------------------------------------

- Settled with Lupin Limited and Lupin Pharmaceuticals; Lupin may sell generic INGREZZA starting March 1, 2038, or earlier under certain circumstances.
- Prior settlements with Sandoz/Crystal and Teva also allow generic entry on March 1, 2038, subject to earlier launch conditions.
- Remaining patent litigation against another ANDA filer is ongoing with trial scheduled for January 2, 2024.
- Agreement will be submitted to FTC and DOJ as required by law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000075/0000914475-23-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447523000075/nbix-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000914475-23-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer